Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon for Chronic Delta Hepatitis
NCT00023322Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Aug 2001
- Primary completion
- May 2012
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a in hepatitis D (HDV), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Histological Response at 3 Years. Started Aug 2001; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT00023322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023322.